tient became febrile, and a pulmonary toilet was performed aggressively. Pan-cultures were obtained 2 days later because of persistent fever. Cerebrospinal fluid collected from a shunt tap by using a sterile technique was negative for infection; no other source of the fever was identified. Empiric vancomycin and levofloxacin therapy was initiated at this time.
Fourth Surgery. On postcranioplasty Day 6, CSF cultures were repeated, at which time Gram-negative rods were identified. Vancomycin was replaced with piperacillin/tazobactam, and the patient returned to surgery for shunt removal and placement of a new EVD at a clean site the following day.
The infectious organism was subsequently identified as P. aeruginosa, whose antibiotic resistance profile is shown in Table 1 . We consulted with the infectious diseases service, and the antibiotic was changed to intravenous imipenem together with intravenous and intrathecal amikacin. Daily CSF cultures obtained from the patient's EVD continued to demonstrate heavy growth of P. aeruginosa, and the ventriculostomy catheter and site were changed without apparent benefit. The patient continued to be febrile.
On postexternalization Day 6, imipenem and amikacin were discontinued, and intravenous and intrathecal colistin were begun. The intrathecal dose consisted of 20 mg colistin concentrated into a 3-ml solution administered once, and then 10 mg colistin was administered once a day thereafter. Cerebrospinal fluid cultures were negative on Day 3 of colistin therapy and remained sterile thereafter. The patient completed a 10-day regimen of intrathecal colistin and continued to receive intravenous colistin until subsequent reinternalization of the VP. The patient was later discharged to an inpatient rehabilitation facility with no further evidence of shunt infection.
Discussion
The polymyxin family of antibiotics, which includes polymyxin B and colistin (the latter, a polymyxin E), was first discovered in 1947 and found to have strong bactericidal activity against Gram-negative organisms. The polymyxin molecule interacts strongly with phospholipids and has been shown to penetrate and disrupt cell membranes. 6 Interestingly, the binding of polymyxin B to lipopolysaccharides of the outer membrane of Gram-negative bacteria also apparently inactivates this molecule and prevents most of the pathophysiological consequences of the release of endotoxin in experimental systems. 9, 10 The clinical use of polymyxin for this indication has yet to be established.
Widespread use of polymyxin B and colistin has been limited by the nephrotoxicity associated with parenteral use, although various ophthalmic, otic, and topical preparations are available. Colistin sulfate is also available in oral form for use in infants and children with diarrhea caused by susceptible bacteria. 6 Polymyxin B was first reported to be used intraventricularly, in combination with an intramuscular injection, in the treatment of five infants with meningitis due to P. pyocyanea. A survey of 33 cases of P. pyocyanea infection at that institution revealed 32 instances of polymyxin B sensitivity, whereas resistances to tetracycline, chloramphenicol, streptomycin, and sulfadimidine were all significantly higher. Of the five reported meningitis cases, all were cleared of infection within 1 month without evidence of direct toxicity or drug resistance.
2 Subsequent use of polymyxins was limited by the emergence of second-and third-generation cephalosporins, which were equally efficacious without the sideeffect profile.
Recently, authors have documented outbreaks of organisms, most commonly Acinetobacter and Pseudomonas, which showed sensitivity to polymyxins only and were treated successfully with intravenous colistin. Notably, these organisms were all resistant to macrolides, carbapenems, and later-generation cephalosporins. One series of 60 infections in 59 patients treated with intravenous colistin included five cases of meningitis, four of which had a good outcome although none had been treated using intrathecal antibiotics. 7 Authors of this series documented iatrogenic renal failure as the most common adverse effect of treatment, which occurred in 27% of treated patients with initially normal renal function. Renal function worsened in 58% of patients with abnormal baseline serum creatinine levels. Two later case reports, featuring the same patient, who had been treated with intravenous colistin for multidrug-resistant A. baumannii meningitis, revealed good recovery without evidence of renal compromise. 4, 5 Modern documentation of intrathecal colistin administration is limited to two reports. Authors of one series documented five cases of catheter-associated carbapenemresistant Acinetobacter ventriculitis; three patients died. 3 The two survivors were treated with intrathecal colistin, although one subsequently died of cardiac arrest approximately 54 days after completing colistin therapy. Postmortem examination in this patient revealed sterile CSF. The first three patients who died in this study all had received intravenous colistin only. Authors of another case report documented a patient who had been treated successfully for highly resistant Acinetobacter ventriculitis by using a 21-day regimen of intrathecal colistin. 11 No adverse renal effect was reported among any of these patients.
The patient in the present case was exposed to prolonged cefazolin prophylaxis while the original EVD was in place. A survey of practice patterns among 36 institutions revealed that 72% used prophylactic antibiotics with all EVDs and intracranial pressure monitors, although there are no studies in which investigators report that this practice produces a statistically significant benefit. 1 Prolonged antibiotic use has been linked to broadened resistance profiles in multiple studies, but only with respect to the specific class of agent used. 1, 4, 7 In addition, the routine use of cefazolin as an antibiotic prophylaxis is frequently cited as an effective strategy in the context of perioperative use to reduce the incidence of resistance to beta-lactamase-stable penicillins, vancomycin, and carbapenems. 1 The patient in the present study exhibited no evidence of cranioplasty wound infection or osteomyelitis implicating the bone flap as the source of the contaminant.
Conclusions
We report the first published case of carbapenem-resistant Pseudomonas ventriculitis successfully treated with intrathecal colistin and no appreciable adverse effect. As antibiotic resistance continues to evolve and novel antibiotics emerge at a very slow pace, colistin administered intrathecally and/or intravenously represents what will likely become an increasingly relevant alternative in the treatment of multiresistant organisms. Although the safety and efficacy of its intrathecal administration have been demonstrated in a few isolated cases, further study is warranted to evaluate the full relevance and potential consequences of its more widespread use.
